FMDV 3C: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Erica Martel (talk | contribs) No edit summary |
Erica Martel (talk | contribs) No edit summary |
||
| Line 11: | Line 11: | ||
== Relevance == | == Relevance == | ||
Vaccines against FMDV are used where the disease is endemic, however, vaccination is not permitted in many countries due to the potential risk for the escape of FMDV. Therefore, there has been interest in producing empty capsid particles for use of potential vaccines against FMD. | Vaccines against FMDV are used where the disease is endemic, however, vaccination is not permitted in many countries due to the potential risk for the escape of FMDV. Therefore, there has been interest in producing empty capsid particles for use of potential vaccines against FMD. | ||
Unfortunately, there has been a number of challenges in this synthetic approach, | Unfortunately, there has been a number of challenges in this synthetic approach, due to 3C's toxicity to cells making it difficult to produce large amounts of processed capside proteins. | ||
To solve this conundrum, different strategies must be analyzed to determine an optimal system for the production of FMDV empty capsid proteins with a limited amount of 3C protease that can stll process P1-2A, with out adverse expression effects. | To solve this conundrum, different strategies must be analyzed to determine an optimal system for the production of FMDV empty capsid proteins with a limited amount of 3C protease that can stll process P1-2A, with out adverse expression effects. This can be | ||
== Structural highlights == | == Structural highlights == | ||
<scene name='70/702408/Fmdv_3c_protease_type_a10/6'>FMDV 3C Protease</scene> | <scene name='70/702408/Fmdv_3c_protease_type_a10/6'>FMDV 3C Protease</scene> | ||
